Cabaletta Bio Inc (CABA) - News Archive

Cabaletta Bio, a clinical-stage biotechnology company, is making significant strides in the development of innovative targeted cell therapies aimed at treating autoimmune diseases. Recent updates from the company highli...

In the expansive realm of autoimmune therapeutics, the quest for efficient, targeted treatments continues unabated. As research and clinical trials advance, each incremental step uncovers new possibilities and refines o...

Cabaletta Bio, a clinical-stage biopharmaceutical company, has recently released positive initial clinical data from their Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201. The company reported that there were...

Cabaletta Bio Receives FDA Orphan Drug Designation for CABA-201 in Systemic Sclerosis TreatmentPhiladelphia-based biotechnology company, Cabaletta Bio, has been granted Orphan Drug Designation (ODD) by the U.S. Food and...

Cabaletta Bio Receives FDA Orphan Drug Designation for CABA-201 in the Treatment of MyositisCabaletta Bio, a leading biotechnology company focused on developing breakthrough targeted cell therapies for autoimmune diseas...

Philadelphia-based biopharmaceutical company, Cabaletta Bio, has recently announced that their investigational therapy, CABA-201, has been granted two new Fast Track Designations by the U.S. Food and Drug Administration...